StockData
Ginkgo Bioworks Holdings, Inc. logo

Ginkgo Bioworks Holdings, Inc. (DNA) company profile

DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.32−0.18 (-2.12%)

Close on Nov 17, 2026Market cap $560.27MP/E –Yield –

About Ginkgo Bioworks

Biological Products, (No Diagnostic Substances), SIC 2836

Ginkgo Bioworks Holdings, Inc. is a biotechnology company that provides biological research and development services and tools rather than manufacturing end products. It operates through two segments: cell engineering and biosecurity. In cell engineering, Ginkgo offers research services, automated laboratory hardware, computational models, and biological data assets to support the discovery, optimization, and production of biological products. In biosecurity, it provides biomonitoring programs via Canopy and threat surveillance and analytics through Horizon. Ginkgo serves commercial clients in pharmaceuticals, biotechnology, agriculture, and industrial biotech, as well as government agencies.

Headquartered in Boston, the company coordinates operations and analyzes data from an international partner network. Its facilities include an automated laboratory, up to 3,000 liters of pilot fermentation capacity, and an approximately 12,000-square-foot greenhouse. The company also maintains a collection of over 315,000 agricultural microorganisms and a metagenomic library of more than 2.7 billion genes. Ginkgo deploys biosecurity sampling nodes at strategic locations such as airports and border checkpoints globally.

Summary of the business section of Ginkgo Bioworks's latest annual report, written by StockData.

Company profile

Company

Legal name
Ginkgo Bioworks Holdings, Inc.
Founded
2008
Headquarters
Boston, MA
Address
27 Drydock Avenue, 8th Floor 02210
Phone
(877) 442-5362
Employees
485, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
DNA
Former tickers
SRNG until Sep 20, 2021
Exchange
NYSE
IPO date
Feb 25, 2021
Shares outstanding
67M, Jul 31, 2026
Public float
$553.00M, Jun 28, 2024
Filer category
Accelerated filer
Stock splits
1-for-40 reverse, Aug 20, 2024
SEC CIK
1830214
CUSIP
37611X209
ISIN
US37611X2099
FIGI
BBG00YPS1KY3
Share class FIGI
BBG00YPS1LT7
EIN
87-2652913

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Reshma P. ShettySee remarks, Director164,705,104
Jason R. KellySee remarks, Director129,065
Steven P. CoenSee remarks50,168
Mark E. DmytrukSee remarks52,132
Christian O. HenryDirector19,310
Sri KosuriDirector24,067
Harry SloanDirector271,418
Ross FubiniDirector10,822
Kathy Hopinkah HannanDirector15,003
Shyam SankarDirector72,372
Myrtle S. PotterDirector10,822

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.71M$3.71M$1.73M$2$93
FY2024$1.23M-$248.05K$1.51M$2$68
FY2023$262.02K-$766.19K$978.50K$14$67
FY2022$262.50K-$152.52M$1.23M$14$63
FY2021$380.74M$237.51M$210.41M$68$84

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOtherTotalvs. prior year
Jason Kelly
Chief Executive Officer
$250.00K$5.45M$5.00K$5.71M+364%
Reshma Shetty
President & Former Chief Operating Officer
$250.00K$3.22M$5.00K$3.48M+183%
Steven Coen
Chief Financial Officer
$433.69K$893.63K$5.00K$1.33M–
Mark Dmytruk
Former Chief Financial Officer
$212.31K$169.63K$5.00K$386.94K-78%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Feb 25, 2021
Offer price
$10.00
Securities offered
150,000,000
Gross proceeds
$1.50B
Lock-up ends (est.)
Aug 24, 2021

“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-fifth of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025 we had 485 employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 7, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 12, 2024DelistingNotice of delisting from exchange (Form 25)
Sep 4, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 14, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 1, 2023Late filingNotification of late filing
Oct 19, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 2, 2022MergerRegistration of securities for a merger or exchange offer (S-4)
Sep 20, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 20, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 17, 2021Name changeName changed from Soaring Eagle Acquisition Corp. to Ginkgo Bioworks Holdings, Inc.
Sep 16, 2021ListingRegistration of securities on an exchange (Form 8-A)
Sep 16, 2021DelistingNotice of delisting from exchange (Form 25)
Sep 2, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 18, 2021Late filingNotification of late filing
May 14, 2021MergerRegistration of securities for a merger or exchange offer (S-4)
Feb 25, 2021IPOInitial public offering priced (424B4 prospectus)
Feb 22, 2021ListingRegistration of securities on an exchange (Form 8-A)
Jan 4, 2021Name changeName changed from Spinning Eagle Acquisition Corp. to Soaring Eagle Acquisition Corp.

See a number that looks wrong?